scholarly journals Zika virus infection in the returning traveller: what every neurologist should know

2018 ◽  
Vol 18 (4) ◽  
pp. 271-277 ◽  
Author(s):  
Sonja Emily Leonhard ◽  
Suzannah Lant ◽  
Bart C Jacobs ◽  
Annelies Wilder-Smith ◽  
Maria Lucia Brito Ferreira ◽  
...  

Zika virus has been associated with a wide range of neurological complications. Neurologists in areas without current active transmission of the virus may be confronted with Zika-associated neurological disease, as a large number of returning travellers with Zika virus infection have been reported and the virus continues to spread to previously unaffected regions. This review provides an overview of Zika virus-associated neurological disease and aims to support neurologists who may encounter patients returning from endemic areas.

Author(s):  
Morganna C. Lima ◽  
Elisa A. N. Azevedo ◽  
Clarice N. L. de Morais ◽  
Larissa I. O. de Sousa ◽  
Bruno M. Carvalho ◽  
...  

Background: Zika virus is an emerging arbovirus of global importance. ZIKV infection is associated with a range of neurological complications such as the Congenital Zika Syndrome and Guillain Barré Syndrome. Despite the magnitude of recent outbreaks, there is no specific therapy to prevent or to alleviate disease pathology. Objective: To investigate the role of P-MAPA immunomodulator in Zika-infected THP-1 cells. Methods: THP-1 cells were subjected at Zika virus infection (Multiplicity of Infection = 0.5) followed by treatment with P-MAPA for until 96 hours post-infection. After that, the cell death was analyzed by annexin+/ PI+ and caspase 3/ 7+ staining by flow cytometry. In addition, the virus replication and cell proliferation were accessed by RT-qPCR and Ki67 staining, respectively. Results: We demonstrate that P-MAPA in vitro treatment significantly reduces Zika virus-induced cell death and caspase-3/7 activation on THP-1 infected cells, albeit it has no role in virus replication and cell proliferation. Conclusions: Our study reveals that P-MAPA seems to be a satisfactory alternative to inhibits the effects of Zika virus infection in mammalian cells.


2019 ◽  
Vol 91 ◽  
pp. 3-10 ◽  
Author(s):  
Vinícius de Melo Marques ◽  
Camilla Sousa Santos ◽  
Isabella Godinho Santiago ◽  
Solomar Martins Marques ◽  
Maria das Graças Nunes Brasil ◽  
...  

2019 ◽  
Vol 113 (12) ◽  
pp. 735-739 ◽  
Author(s):  
Bramuel Kisuya ◽  
Moses M Masika ◽  
Esto Bahizire ◽  
Julius O Oyugi

Abstract Background The Zika virus pandemic in South America in 2015–2016 and the association of Zika virus infection with neurological complications such as microcephaly in newborns distressed the global community. There is limited data on the prevalence of Zika virus in Kenya despite evidence of its circulation in East Africa. This study aimed at assessing the seroprevalence of Zika virus in selected areas in Kenya. Methods Healthy adult human sera originally collected from Nairobi, Eldoret and Kisumu from 2009 to 2014 and archived at the University of Nairobi laboratories were examined for Zika virus antibodies. An IgG-based ELISA was used to screen 577 sera. Any serum tested positive by ELISA was confirmed for Zika virus infection by plaque reduction neutralization test (PRNT). Results The seroprevalence of Zika virus in the study population was about 0.2 % (1/577) as confirmed by PRNT. Additionally, three sera that were false positive by ELISA for Zika virus were confirmed as positive for dengue virus by PRNT. Conclusion There was evidence of low previous exposure to Zika virus in the study population. Of the three regions in Kenya where sera for this study were obtained, only Kisumu County had one case of previous exposure to Zika virus.


2016 ◽  
Vol 16 (7) ◽  
pp. 771-772 ◽  
Author(s):  
Emanuele Nicastri ◽  
Concetta Castilletti ◽  
Antonino Di Caro ◽  
Maria R Capobianchi ◽  
Giuseppe Ippolito

2021 ◽  
Author(s):  
Mariah Hassert ◽  
Tara L. Steffen ◽  
Stephen Scroggins ◽  
Abigail K. Coleman ◽  
Enbal Shacham ◽  
...  

The 2015/16 Zika virus epidemic in South and Central America left the scientific community urgently trying to understand the factors that contribute to Zika virus pathogenesis. Because multiple other flaviviruses are endemic in areas where Zika virus emerged, it is hypothesized that a key to understanding Zika virus disease severity, is to study Zika virus infection in the context of prior flavivirus exposure. Human and animal studies have highlighted the idea that having been previously exposed to a different flavivirus may modulate the immune response to Zika virus. However, it is still unclear how prior flavivirus exposure impacts Zika viral burden and disease. In this murine study, we longitudinally examine multiple factors involved in Zika disease, linking viral burden with increased neurological disease severity, weight loss, and inflammation. We show that prior heterologous flavivirus exposure with dengue virus type 2 or 3, or the vaccine strain of yellow fever, provides protection from mortality in a lethal Zika challenge. However, reduction in viral burden and Zika disease varies depending on the infecting primary flavivirus; with primary Zika infection being most protective from Zika challenge, followed by dengue 2, with yellow fever, and dengue 3 protecting against mortality but showing a more severe disease. This study demonstrates the variation in protective effects of prior flavivirus exposure on Zika virus pathogenesis, and identifies distinct relationships between primary flavivirus infection and the potential for Zika virus disease. IMPORTANCE: The emergence and re-emergence of various vector-borne diseases in recent years highlights the need to understand the mechanisms of protection for each pathogen. In this study, we investigated the impact of prior exposure to Zika, dengue serotypes 2 or 3 or the vaccine strain of yellow fever on pathogenesis and disease outcomes in a mouse model of Zika virus infection. We found that prior exposure to a heterologous flavivirus was protective from mortality, and to varying degrees, prior flavivirus exposure was protective against neurological disease, weight loss, and severe viral burden during a lethal Zika challenge. Using a longitudinal and cross-sectional study design, we were able to link multiple disease parameters including viral burden with neurological disease severity, weight loss, and inflammatory response in the context of flavivirus infection. This study demonstrates a measurable but varied impact of prior flavivirus exposure in modulating flavivirus pathophysiology. Given the cyclic nature of most flavivirus outbreaks, this work will contribute to the forecasting of disease severity for future outbreaks.


2020 ◽  
Vol 12 (547) ◽  
pp. eaau9135 ◽  
Author(s):  
So-Yon Lim ◽  
Christa E. Osuna ◽  
Katharine Best ◽  
Ray Taylor ◽  
Elsa Chen ◽  
...  

Zika virus infection in humans has been associated with serious reproductive and neurological complications. At present, no protective antiviral drug treatment is available. Here, we describe the testing and evaluation of the antiviral drug, galidesivir, against Zika virus infection in rhesus macaques. We conducted four preclinical studies in rhesus macaques to assess the safety, antiviral efficacy, and dosing strategies for galidesivir (BCX4430) against Zika virus infection. We treated 70 rhesus macaques infected by various routes with the Puerto Rico or Thai Zika virus isolates. We evaluated galidesivir administered as early as 90 min and as late as 72 hours after subcutaneous Zika virus infection and as late as 5 days after intravaginal infection. We evaluated the efficacy of a range of galidesivir doses with endpoints including Zika virus RNA in plasma, saliva, urine, and cerebrospinal fluid. Galidesivir dosing in rhesus macaques was safe and offered postexposure protection against Zika virus infection. Galidesivir exhibited favorable pharmacokinetics with no observed teratogenic effects in rats or rabbits at any dose tested. The antiviral efficacy of galidesivir observed in the blood and central nervous system of infected animals warrants continued evaluation of this compound for the treatment of flaviviral infections.


10.3823/2579 ◽  
2018 ◽  
Vol 11 ◽  
Author(s):  
Modesto Leite Rolim Neto ◽  
Arthur Rafhael Amorim Alves Esmeraldo ◽  
Dábylla Cynthia Carvalho Bezerra ◽  
Francisca Patricia de Melo Santos Leite ◽  
Cristiano Nogueira Marques ◽  
...  

The evidences highlight that 13.5% of the echocardiographic studies performed in children with congenital Zika virus infection presented amendments of congenital heart disease (CHD). Several recent studies have shown that the pathogenesis of neurological complications of the Zika virus, as Guillain-Barre Syndrome, in relation to other clinical manifestations there are still no conclusive findings. Scientific studies have observed the possibility of cardiac involvement be underdiagnosed due to the mercy of the infection per ZIKV, in their majority.


2020 ◽  
Vol 117 (49) ◽  
pp. 31365-31375
Author(s):  
Rachel P. M. Abrams ◽  
Adam Yasgar ◽  
Tadahisa Teramoto ◽  
Myoung-Hwa Lee ◽  
Dorjbal Dorjsuren ◽  
...  

When Zika virus emerged as a public health emergency there were no drugs or vaccines approved for its prevention or treatment. We used a high-throughput screen for Zika virus protease inhibitors to identify several inhibitors of Zika virus infection. We expressed the NS2B-NS3 Zika virus protease and conducted a biochemical screen for small-molecule inhibitors. A quantitative structure–activity relationship model was employed to virtually screen ∼138,000 compounds, which increased the identification of active compounds, while decreasing screening time and resources. Candidate inhibitors were validated in several viral infection assays. Small molecules with favorable clinical profiles, especially the five-lipoxygenase–activating protein inhibitor, MK-591, inhibited the Zika virus protease and infection in neural stem cells. Members of the tetracycline family of antibiotics were more potent inhibitors of Zika virus infection than the protease, suggesting they may have multiple mechanisms of action. The most potent tetracycline, methacycline, reduced the amount of Zika virus present in the brain and the severity of Zika virus-induced motor deficits in an immunocompetent mouse model. As Food and Drug Administration-approved drugs, the tetracyclines could be quickly translated to the clinic. The compounds identified through our screening paradigm have the potential to be used as prophylactics for patients traveling to endemic regions or for the treatment of the neurological complications of Zika virus infection.


Sign in / Sign up

Export Citation Format

Share Document